Beta Drugs Announces 1:20 Bonus Share Issue to Reward Shareholders

Beta Drugs Limited, a leading pharmaceutical company specializing in oncology products, has announced a bonus share issue in the ratio of 1:20. This means shareholders will receive one new equity share for every 20 shares held. The company's board approved this move to reward its investors and improve stock liquidity. This decision comes on the heels of Beta Drugs' strong financial performance and growth in the oncology segment. The record date for determining eligible shareholders will be announced separately. This bonus issue is subject to necessary approvals and is expected to be completed within the regulatory timeframe.

Source: Beta Drugs Limited BSE Filing, February 5, 2025